#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
proLékaře.cz / Topic

Oncological Treatment

We recommend zak

With Prof. Pavel Žák about Current Trends and Future Perspectives in Bone Marrow Transplantation and the Role of Carmustine in this Context

10. 6. 2024 Source: Oncological Treatment

Hematopoietic stem cell transplantation has an indispensable place in the treatment of hemato-oncological diseases. We discuss current trends in this area, the significance and benefits of carmustine, the choice between BEAM and TEAM regimens, and the future of bone marrow transplantation in the context of new technologies with the head of the 4th Department of Hematology of the Faculty of Medicine, Charles University and University Hospital Hradec Králové, Prof. MUDr. Pavel Žák, Ph.D.

prof. Brodák

Prof. Miloš Broďák: Introduction of new drugs has significantly improved results even in progressive and recurrent prostate cancers

The prognosis and treatment outcomes for patients with various stages of prostate cancer have…
3. 4. 2024 Source: Oncological Treatment
prostat

Use of Testosterone Level as a Biomarker for Quality of Life in Patients with Prostate Cancer

In the treatment of prostate cancer, in addition to surgical treatment, stereotactic body…
6. 12. 2023 Source: Oncological Treatment
Articles on this topic
PROSTATA

Benefit of Short-term Androgen-deprivation Therapy Added to Radiotherapy of Localized Prostate Cancer for Long-term Survival

Androgen-deprivation therapy is associated with several adverse effects that also affect…
26. 10. 2023 Source: Oncological Treatment
PROSTATA- RENTGEN

Multimodal Treatment of Prostate Cancer in a Patient with Exceptionally Long Overall Survival −⁠ Case Report

A recently published case study by Romanian authors presents a rare instance of long-term…
26. 10. 2023 Source: Oncological Treatment
lymfom dlbcl

Comparison of BEAM and TEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Lymphomas

At the beginning of this year, one of the few studies comparing the most commonly used…
13. 6. 2023 Source: Oncological Treatment
ct rakovina prostaty

Results of Long-Term Follow-Up of Patients with Prostate Adenocarcinoma After Radiotherapy with Short-Term Androgen Deprivation

Adding short-term androgen deprivation to radiotherapy improved overall survival,…
21. 3. 2023 Source: Oncological Treatment
rakovina plic buňky

Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression

Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth…
21. 11. 2022 Source: Oncological Treatment
játra lupa

What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?

Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20…
31. 10. 2022 Source: Oncological Treatment
nádor výzkum léčby rakoviny

Nearly 20 Years with Bevacizumab Has Brought Hope for Patients and Deeper Understanding of Solid Tumors

Bevacizumab is among the first targeted therapies used in oncology. For many indications where…
19. 8. 2022 Source: Oncological Treatment
rakovina buňky

Erlotinib in Conditions of Routine Clinical Practice

The patient population in clinical trials is always somewhat selected. Only a well-conducted…
18. 5. 2022 Source: Oncological Treatment
nádor tlustého střeva

Safety of Long-Term Therapy with Bevacizumab in Oncological Patients

The angiogenesis inhibitor bevacizumab is typically administered long-term. Therefore, a study…
21. 4. 2022 Source: Oncological Treatment
MUDr_Pavel_Jindra

Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology

“Based on our experience so far, biosimilars represent an effective and safe alternative to…
24. 3. 2022 Source: Oncological Treatment
mladá žena u gynekologa

Protection of Ovarian Function During Breast Cancer Treatment

Women diagnosed with breast cancer of childbearing age are concerned about how to maintain…
20. 12. 2021 Source: Oncological Treatment
léky_peníze_prasátko_rovnováha

Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising…
22. 11. 2021 Source: Oncological Treatment
plíce

Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment

The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02,…
15. 10. 2021 Source: Oncological Treatment
Onkologická pacientka chemoterapie

Efficacy and Safety of Gefitinib in Combination with Chemotherapy vs. Chemotherapy Alone in the Treatment of Advanced NSCLC

Non-small cell lung cancer (NSCLC) remains a disease with high mortality. The meta-analysis…
15. 10. 2021 Source: Oncological Treatment

Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer

Biosimilar drugs are essentially analogous to generics for biological medicines. The patent…
15. 9. 2021 Source: Oncological Treatment
1 2
Subscribe
Most read on this topic
Journal on this topic
Issue 6
Clinical Oncology
Issue 828
BMC Cancer
Issue 1 - Diabetologie
Trade Medicine Journal
Related topic
Interesting links
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#